Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-1320
Immunoglobulins Market is estimated to value over CAGR of over 6.4% during the forecast period 2022 to 2028. Immunoglobulins are known as glycoproteins which are formed in the blood plasma. This, in turn, reacts to antigens that are in the body. Intravenous immunoglobulin is a blood product which is arranged from the serum and accounts to nearly 1,000 to 10,000 donors per donor. Such immunoglobulins are administered to people who are afflicted with weak immune systems. An illness such as immunodeficiency could be inherent in the body or could be attributed to the exposure of infections, by way of bodily fluids as well as chemotherapy and cancer drugs. The aging process could be another factor and can even make a person susceptible to a poor immune system. Fast-paced and unbalanced lifestyles have led people to take to unhealthy diets and this, in turn, has caused them to develop weak immune systems. Attributes such as reduced sleeping patterns, high levels of stress, and unhealthy diets are factors which are contributing to the ever-growing presence of the illness known as immunodeficiency disorder. Treatment of this nature is used for patients who are afflicted with antibody deficiencies. The global market for geriatric population has gained a strong foothold since there is an exponential rise in the number of hemophilic patients, technological prowess for the boost in production of intravenous immunoglobulin and positive strides in the purification methodologies. Although, stringent government guidelines with respect to the detrimental side-effects of intravenous immunoglobulin could hamper the global immunoglobulins market growth. Going by the segmentation of component, the market for immunoglobulin is divided into IgA, IgD, IgM, IgG, IgE. The rise in the patient pool and a multitude of neurological disorders are prompting the need for speedy and dependable treatment and these are factors which have contributed significantly towards the usage of intravenous immunoglobulin in the treatment of unlabeled indications. To add to this, a hike in the research and development investments for novel goods from private and government officiated organizations alike, are expected to further augment the global immunoglobulins market size. Application-wise, the market is fragmented into Guillain-Barre syndrome, CIDP (chronic inflammatory demyelinating polyneuropathy), myasthenia gravis, immunodeficiency diseases, inflammatory myopathies, hypogammaglobinemia, thrombocytopenic purpura, specific antibody deficiency, multifocal motor neuropathy and others. The major players in the market for immunoglobulins include BDI Pharma (US), Grifols Inc. (Spain), Abeona Therapeutics (US), Biotest AG. (Germany), Baxter (US), Octapharma (Switzerland), China Biologic Products, Inc. (China), Kedrion S.p.A (US), Shire (Republic of Ireland) and CSL Behring (US) Immunoglobulins Market Segmentation: By Application Hypogammaglobinemia Chronic Inflammatory Demyelinating polyneuropathy (CIDP) Primary Immunodeficiency Diseases Myasthenia Gravis Multifocal Motor Neuropathy Idiopathic Thrombocytopenic Purpura (ITP) Inflammatory Myopathies Specific Antibody Deficiency Guillain-Barre Syndrome Guillain-Barre Syndrome Others By Product IGG IGA IGE IGD By Mode of Delivery • Intravenous o 5% Concentration o 10% Concentration o Other Concentrations • Subcutaneous o 6.5% Concentration o 20% Concentration o Other Concentrations By Region Europe North America Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global immunoglobulins market by product, by application, by mode of delivery and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Immunoglobulins are known as glycoproteins which are formed in the blood plasma. This, in turn, reacts to antigens that are in the body. Intravenous immunoglobulin is a blood product which is arranged from the serum and accounts to nearly 1,000 to 10,000 donors per donor. Such immunoglobulins are administered to people who are afflicted with weak immune systems. An illness such as immunodeficiency could be inherent in the body or could be attributed to the exposure of infections, by way of bodily fluids as well as chemotherapy and cancer drugs. The aging process could be another factor and can even make a person susceptible to a poor immune system.
Fast-paced and unbalanced lifestyles have led people to take to unhealthy diets and this, in turn, has caused them to develop weak immune systems. Attributes such as reduced sleeping patterns, high levels of stress, and unhealthy diets are factors which are contributing to the ever-growing presence of the illness known as immunodeficiency disorder.
Treatment of this nature is used for patients who are afflicted with antibody deficiencies. The global market for geriatric population has gained a strong foothold since there is an exponential rise in the number of hemophilic patients, technological prowess for the boost in production of intravenous immunoglobulin and positive strides in the purification methodologies. Although, stringent government guidelines with respect to the detrimental side-effects of intravenous immunoglobulin could hamper the global immunoglobulins market growth.
Going by the segmentation of component, the market for immunoglobulin is divided into IgA, IgD, IgM, IgG, IgE. The rise in the patient pool and a multitude of neurological disorders are prompting the need for speedy and dependable treatment and these are factors which have contributed significantly towards the usage of intravenous immunoglobulin in the treatment of unlabeled indications. To add to this, a hike in the research and development investments for novel goods from private and government officiated organizations alike, are expected to further augment the global immunoglobulins market size.
Application-wise, the market is fragmented into Guillain-Barre syndrome, CIDP (chronic inflammatory demyelinating polyneuropathy), myasthenia gravis, immunodeficiency diseases, inflammatory myopathies, hypogammaglobinemia, thrombocytopenic purpura, specific antibody deficiency, multifocal motor neuropathy and others.
The major players in the market for immunoglobulins include BDI Pharma (US), Grifols Inc. (Spain), Abeona Therapeutics (US), Biotest AG. (Germany), Baxter (US), Octapharma (Switzerland), China Biologic Products, Inc. (China), Kedrion S.p.A (US), Shire (Republic of Ireland) and CSL Behring (US)
Immunoglobulins Market Segmentation: By Application
By Product
By Mode of Delivery
• Intravenous o 5% Concentration o 10% Concentration o Other Concentrations • Subcutaneous o 6.5% Concentration o 20% Concentration o Other Concentrations
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Immunoglobulins Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Immunoglobulins Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Immunoglobulins Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Immunoglobulins Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Immunoglobulins Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Hypogammaglobinemia 7.2. Chronic Inflammatory Demyelinating polyneuropathy (CIDP) 7.3. Primary Immunodeficiency Diseases 7.4. Myasthenia Gravis 7.5. Multifocal Motor Neuropathy 7.6. Idiopathic Thrombocytopenic Purpura (ITP) 7.7. Inflammatory Myopathies 7.8. Specific Antibody Deficiency 7.9. Guillain-Barre Syndrome 7.10. Others 8. Global Immunoglobulins Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. IGG 8.2. IGA 8.3. IGE 8.4. IGD 9. Global Immunoglobulins Market, By Mode of Delivery Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Intravenous 9.1.1. 5% Concentration 9.1.2. 10% Concentration 9.1.3. Other Concentrations 9.2. Subcutaneous 9.2.1. 6.5% Concentration 9.2.2. 20% Concentration 9.2.3. Other Concentrations 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. BDI Pharma (US) 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Grifols Inc. (Spain) 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Abeona Therapeutics (US). 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Biotest AG. (Germany) 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Baxter (US) 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Octapharma (Switzerland) 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. China Biologic Products, Inc. (China) 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Kedrion S.p.A (US) 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Shire (Republic of Ireland) 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. CSL Behring (US) 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nation 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics